J&J gives pi­o­neer­ing stem cell biotech its first Big Phar­ma deal, part­ner­ing on iP­SC CAR-T and CAR-NK

Late last sum­mer, one of the ear­li­est stem cell ther­a­py com­pa­nies got two gov­ern­ment de­ci­sions in the span of three weeks: The USP­TO grant­ed them a patent for iP­SC-de­rived CAR-T cells, and then the FDA cleared them for their first-in-hu­man CAR-NK tri­al.

Yes­ter­day, the two tech­nolo­gies land­ed them an up-to $3.1 bil­lion deal.

Fate Ther­a­peu­tics and J&J an­nounced a glob­al col­lab­o­ra­tion that will pay Fate $100 mil­lion up­front and a trove of po­ten­tial mile­stones to de­vel­op mul­ti­ple CAR-T and CAR-NK ther­a­pies. It’s the first Big Phar­ma part­ner­ship Fate has an­nounced in their 13-year ex­is­tence and the largest, al­though at least one long­time fol­low­er thought they could have land­ed more.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER